About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Improving the Reporting of Medication Errors and Adverse Events at the Veterans Affairs–New York Harbor Healthcare System
The authors discuss the creation of a “culture of safety,” brought about in part by a confidential error-reporting system. Their experience has the potential to encourage employees to report medication errors without fear of blame.
Simona Peker, MS/MLS, MSA, PharmD, Dea Hughes, MPH, Kim Arslanian, MT, MBA, and Joseph Aprile, RPh, MS
How and whether to treat older children and adolescents with elevated cardiac risk factors presents a dilemma for health care providers. The authors discuss screening, the problem of compliance with lifestyle modifications, and the ramifications of statin therapy for these young patients.
Peter J. Morelli, MD, and Rula Balluz, MD, MPH
Foot care programs decrease the risk of foot ulcers by 13-fold. The authors found that the more frequently diabetic patients checked their feet, the greater their knowledge of their condition.
Fadia T. Shaya, PhD, MPH, Nneka Onwudiwe, PharmD, Navendu Samant, MA, Reed Winston, MD, PhD, Wallace Johnson, MD, Aurelia Laird, RN, Faye Larkins, RN, MPH, and Gabriel E. Shaya
Presentations cover glycemic control to reduce macrovascular events; the need to achieve LDL-cholesterol goals; and the beneficial effects of sitagliptin/metformin on blood glucose. Forthcoming products from Sanofi-Aventis are also summarized.
Topics include amlodipine/olmesartan medoxomil (Azor) for hypertension; dexrazoxane (Totect) after chemotherapy; and a topical thrombin (Evithrom) to help control bleeding during surgery.
Marvin M. Goldenberg, PhD, RPh, MS
David Nash, MD, MBA, discusses the role of Pennsylvania’s Patient Safety Authority in reducing medication errors.
David Nash, MD, MBA
Stephen Barlas questions whether the federal government has made enough progress to prevent an influenza pandemic in the U.S.
Matthew Grissinger, RPh, FASCP, offers ways to help patients avoid unintentionally exceeding recommended doses of acetaminophen, a common problem often resulting from inadequate product labeling.
Matthew Grissinger, RPh, FASCP
From Afluria to Voltaren, P&T presents the latest studies and information about FDA approvals, new indications, and industry updates.
The authors review extended-release paliperidone (Invega) for the treatment of schizophrenia.
Benjamin Chavez, PharmD, Devon A. Sherwood, PharmD, and Michele McCue, BS